Recent Articles in COVID-19

Jiangsu Recbio Technology and Shenzhen Rhegen Biotech established a joint JV to pool their knowledge of mRNA vaccine technology. Recbio has built a portfolio of 11 vaccine candidates, while Rhegen believes it has the world's leading mRNA technology. Rhegen  has developed three technology platforms for mRNA vaccines. The JV plans to apply the latest mRNA knowledge and novel adjuvant technology to develop a next-gen COVID-19 vaccine along with vaccines for other major infectious diseases and therapeutic cancer vaccines. More details....

Share this with colleagues:

Clover, a Chengdu vaccine/biologic company, reported its adjuvanted protein-based COVID-19 vaccine candidate met its endpoints in a global, 30,000 person pivotal Phase II/II trial. SCB-2019 (CpG 1018/Alum) prevented 100% of severe COVID-19 vaccine and hospitalizations in all SARS-CoV-2 strains. Overall efficacy was 67% against COVID-19 of any severity caused by any strain. It posted 79% overall efficacy against COVID-19 of any severity in Delta subjects. Clover's trial was supported by CEPI, the Coalition for Epidemic Preparedness Innovations. More details....

Share this with colleagues:

Cue Health, a San Diego company with a home testing kit for COVID-19, filed for a $180 million IPO on NASDAQ that values the company at $2 billion. Shanghai's Decheng Capital participated in several Cue fundraisings including the company's $235 million round in May. Cue intends to build a broad platform to address a user's healthcare needs. The company's tests consist of a single-use cartridge that is compatible with the Cue Reader and sends the results to Cue's healthcare app on a smart phone. More details....

Share this with colleagues:

Shanghai Everest Medicines announced a $500 million two-part deal with Providence Therapeutics of Calvery, Canada for mRNA products. Initially, Everest will acquire China-Asia rights to Providence's mRNA clinical stage COVID-19 vaccine for $50 million upfront and $100 million in profit sharing. The two companies will also enter a 50/50 global collaboration for two additional Providence mRNA prophylactic or therapeutic products, also with a $50 million upfront payment and up to $300 million in sales milestones (which will be paid in Everest stock). More details....

Stock Symbol: (HK 1952)

Share this with colleagues:

Sinovac Biotech reported that a third dose of its inactivated SARS-CoV-2 vaccine improved the protection of CoronaVac® by 60%, including protection from the Delta variant. The third dose was administered six months after the second shot, when the efficacy of the vaccine was already in decline. CoronaVac® was approved by WHO under emergency rules. Sinovac said the study provides a "theoretical basis" for a third dose of the vaccine, implying more studies would be required before regulatory approval. More details....

Stock Symbol: (NSDQ: SVA)

Share this with colleagues: